Open for forecastingClinical TrialsReleased Dec 17, 2025

BiRCh (brensocatib) Phase 2b for CRSsNP

0 models evaluated0 runs0 votes
Run this in the Arena

Trial setup

- Trial: BiRCh, Phase 2b, randomized, double-blind, placebo-controlled. - Population: chronic rhinosinusitis without nasal polyps (CRSsNP). - Arms: brensocatib 10 mg; brensocatib 40 mg; placebo. - Primary endpoint: change from baseline in sinus Total Symptom Score (sTSS) at Week 24. - Safety: treatment-emergent adverse events (TEAEs) reported as % of participants with >=1 TEAE.

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.